Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail

This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.

Detalles Bibliográficos
Autores principales: van den Boom, Louisa, Stuecher, Theresa, Mader, Julia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449226/
https://www.ncbi.nlm.nih.gov/pubmed/34567554
http://dx.doi.org/10.1002/ccr3.4811
Descripción
Sumario:This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.

Ejemplares similares